Metastatic Cancer Treatment Market Trends
The increasing patient pool for cancer as well as the rising geriatric population and life expectancy are expected to be the major factors for the growth of the market. Pharmaceutical giants such as Roche and Novartis are investing in the R&D for the development of innovative and improved medication for the treatment of the disease. Rising interest in the biologics medication especially monoclonal antibodies is also expected to fuel the growth of the market.
The increasing patient pool for cancer as well as the rising geriatric population and life expectancy are expected to be the major factors for the growth of the market. Pharmaceutical giants such as Roche and Novartis are investing in the R&D for the development of innovative and improved medication for the treatment of the disease. Rising interest in the biologics medication especially monoclonal antibodies is also expected to fuel the growth of the market.
- TAGS
- healthcare-industry
- healtcareit
- healtcare
- news
- bisresearch
- lung-cancer-drugs-market
- lung-cancer-market
- colorectal-cancer-market
- prostate-cancer-market
- melanoma-market
- melanoma-treatment-market
- oncology-drugs-market
- cancer-treatment-market
- oncology-market
- breast-cancer-market
- metastasis-cancer-market
- metastatic-cancer-market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
155 F. Hoffmann-La Roche AG: Product Portfolio for<br />
<strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
156 F. Hoffmann-La Roche AG: Overall Financials<br />
(2014-2017)<br />
157 F. Hoffmann-La Roche AG: Product Sales by<br />
Region (2014-2017)<br />
158 F. Hoffmann-La Roche AG: Revenue by Division<br />
(2014-2017)<br />
159 F. Hoffmann-La Roche AG: Revenue by<br />
Pharmaceutical Sub-Segment (2014-2017)<br />
160 F. Hoffmann-La Roche AG: Global Presence<br />
161 F. Hoffmann-La Roche AG: SWOT Analysis<br />
162 JOHNSON & JOHNSON: Overall Product Portfolio<br />
163 JOHNSON & JOHNSON: Product Portfolio for<br />
<strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
164 JOHNSON & JOHNSON: Overall Financials (2014-<br />
2017)<br />
165 JOHNSON & JOHNSON: Revenue by Business<br />
segment (2014-2017)<br />
166 JOHNSON & JOHNSON: Revenue by Geography<br />
(2014-2017)<br />
167 JOHNSON & JOHNSON: Global Presence<br />
168 JOHNSON & JOHNSON: SWOT Analysis<br />
169 Merck & Co., Inc.: Overall Product Portfolio<br />
170 Merck & Co., Inc.: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
171 Merck & Co., Inc.: Overall Financials (2014-2017)<br />
172 Merck & Co., Inc.: Revenue by Business segment<br />
(2014-2017)<br />
173 Merck & Co., Inc.: Revenue by Geography (2014-<br />
2017)<br />
174 Merck & Co., Inc.: Global Presence<br />
175 Merck & Co., Inc.: SWOT Analysis<br />
176 Novartis AG: Overall Product Portfolio<br />
177 Novartis AG: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
178 Novartis AG: Overall Financials (2014-2017)<br />
179 Novartis AG: Revenue by Geography (2014-2017)<br />
180 Novartis AG: Revenue by Business Segment<br />
(2014-2015)<br />
181 Novartis AG: Revenue by Buisness Segment<br />
(2016-2017)<br />
182 Novartis AG: Global Presence<br />
183 Novartis AG: SWOT Analysis<br />
184 Pfizer, Inc.: Overall Product Portfolio<br />
185 Pfizer, Inc.: Product Portfolio for <strong>Metastatic</strong><br />
<strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
186 Pfizer, Inc.: Overall Financials (2014-2017)<br />
187 Pfizer, Inc.: Revenue by Business segment (2014-<br />
2017)<br />
188 Pfizer, Inc.: Revenue by Geography (2014-2017)<br />
189 Pfizer, Inc.: Global Presence<br />
190 Pfizer, Inc.: SWOT Analysis<br />
191 SANOFI: Overall Product Portfolio<br />
192 SANOFI: Product Portfolio for <strong>Metastatic</strong> <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong><br />
193 SANOFI: Overall Financials (2014-2017)<br />
194 SANOFI: Revenue by Business Segment (2014-<br />
2015)<br />
195 SANOFI: Revenue by Business Segment (2016-<br />
2017)<br />
196 SANOFI: Revenue by Geography (2014-2015)<br />
197 SANOFI: Revenue by Geography (2016-2017)<br />
198 SANOFI: Global Presence<br />
199 SANOFI: SWOT Analysis<br />
200 Takeda Pharmaceutical Company Limited: Overall<br />
Product Portfolio<br />
201 Takeda Pharmaceutical Company Limited: Product<br />
Portfolio for <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
202 Takeda Pharmaceutical Company Limited: Overall<br />
Financials (2014-2017)<br />
203 Takeda Pharmaceutical Company Limited:<br />
Revenue by Business segment (2014-2017)<br />
204 Takeda Pharmaceutical Company Limited:<br />
Revenue by Geography (2014-2017)<br />
205 Takeda Pharmaceutical Company Limited: Global<br />
Presence<br />
206 Takeda Pharmaceutical Company Limited: SWOT<br />
Analysis<br />
207 bluebird bio, Inc.: Product Pipeline for <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong><br />
208 Clovis Oncology, Inc.: Product Pipeline for <strong>Cancer</strong><br />
<strong>Treatment</strong> <strong>Market</strong><br />
209 IDERA PHARMACEUTICALS, INC.: Product<br />
Pipeline for <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
210 eTheRNA immunotherapies NV: Product Pipeline<br />
for <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
211 Global <strong>Metastatic</strong> <strong>Cancer</strong> <strong>Treatment</strong> <strong>Market</strong><br />
Segmentation<br />
212 Considered Factors for Data Prediction & Modeling<br />
sales@bisresearch.com www.bisresearch.com 7
Change language